# Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

> **NCT07368270** · PHASE1 · RECRUITING · sponsor: **Jiangsu Topcel-KH Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-PD1 armored CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT07368270
- **Lead sponsor:** Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-01
- **Final completion:** 2029-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07368270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07368270, "Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07368270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*